Warren Buffet makes the news each year for his letter to Berkshire Hathaway shareholders. By employing his uniquely wry and contrarian style and covering many topics that have little direct bearing on Berkshire’s results or prospects, Buffet has taken one of the staple obligations of a public company CEO, and turned it into something much larger — a kind of State of the Union from the desk of one of our most important business leaders.
The Westwicke Blog is designed to deliver information and insights into the ever-changing world of healthcare communications.
No one could have predicted the events of 2020. However, given the strength and evolution of the healthcare and biotech industry over the past 12 months, the team at Westwicke has some ideas about how the upcoming year may unfold. Below, we provide insight into what the new year may bring.
Every investor’s decision-making process is unique. However, understanding their primary concerns and anticipating common questions can help you better align your message with what the investor needs to hear in order to come to an investment decision.
There are six questions in particular that investors will ask about you and your market opportunity before making an investment decision. Use the checklist below to prepare your answers to these common investor questions prior to your next meeting.
After nearly 20 years of working in healthcare communications, the excitement never gets old for me. What’s not to love about an industry that’s critical to life itself, rife with issues and controversy, and delivers a solid dose of the unexpected on a daily basis?
In my mind, a highlight is the problem solving our job requires every day. Whether pursuing an opportunity, managing an issue or leveraging an insight, it’s our responsibility to chart the path forward on behalf of our clients.
After a long period of market uncertainty driven by the COVID-19 pandemic, the second half of 2020 saw market conditions improve for IPOs with a recent flurry of tech companies making their debut. With increased demand to access the public markets, a strong pipeline of companies set to come to market is shaping up quickly for all of 2021.
Properly positioning your story within the investment community can help you build a quality, long-term shareholder base and enhance equity market value. To develop an effective investor relations strategy, you must understand how to best interact with investors, stay visible, and adapt to deliver both good news and bad.
In the wake of the coronavirus pandemic, the IPO market may never look the same. The swift shift to virtual roadshows, for example, has demonstrated efficiencies that are likely to make digital alternatives stick even after regular business travel resumes. But beyond the operational changes behind preparing a company to go public, the market has seen growing interest in alternatives to the IPO itself.
As life science and medical device companies seek regulatory approval for their products, they will likely encounter difficult disclosure decisions around clinical and regulatory events. Clinical trial data and milestones can present great opportunities as well as significant challenges.
The challenges of functioning successfully in an extended COVID-19 environment have presented many new ways of doing business. This is especially evident for events such as non-deal roadshows (NDRs).
Over the past several months, interest in special purpose acquisition companies (SPACs) has grown exponentially. SPAC transactions serve as an alternative to traditional IPOs, and while they have existed for many years, they are currently experiencing a resurgence within several industries.